Video

Dr. Weber on Results of the COMBI-AD Trial in Stage III BRAF-Mutant Melanoma

Jeffrey S. Weber, MD, PhD, discusses the results of the phase 3 COMBI-AD trial with dabrafenib plus trametinib in patients with resected, stage III BRAF V600E/K–mutant melanoma.

Jeffrey S. Weber, MD, PhD, the deputy director of NYU Langone Health’s Perlmutter Cancer Center; Laura and Isaac Perlmutter Professor of Oncology in the Department of Medicine at NYU Grossman School of Medicine; and the 2016 Giant of Cancer Care® in Melanoma, discusses the results of the phase 3 COMBI-AD trial with dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with resected, stage III BRAF V600E/K–mutant melanoma.

The COMBI-AD trial results are impressive, with a plateau in the 5-year relapse-free survival (RFS) curve, according to Weber. After a median follow-up of 60 months, the data show a 5-year RFS of 52% for patients treated with dabrafenib plus trametinib, says Weber.

The phase 3 CheckMate-238 trial was an adjuvant trial that randomized patients with resected stage IIIB/C or stage IV melanoma to receive either nivolumab (Opdivo) or ipilimumab (Yervoy). If the results from COMBI-AD are compared with the 4-year results from the CheckMate-238 trial, the 4-year survival seen with nivolumab is the same as the 5-year survival seen with dabrafenib/trametinib, notes Weber. However, a large number of patients with stage IIIA disease included in the COMBI-AD trial did well but were not included in CheckMate-238. Additionally, patients with stage IV resected disease were included in the CheckMate-238 trial and would probably not do well with the COMBI-AD regimen, explains Weber.

Nonetheless, evidence of a plateau in the RFS curve is encouraging, according to Weber. Finally, when looking at the survival of any of the prognostic factors in the COMBI-AD trial, there appears to be a clear benefit for patients with stage IIIA-C disease, concludes Weber.

Related Videos
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD